Lenalidomide is an oral immunomodulatory drug that is mainly used to treat blood cancers such as myelodysplastic syndrome, multiple myeloma, and lymphoma. It has been developed to minimize dose-limiting side effects of thalidomide such as constipation, neuropathy, sedation, and thromboembolism. The drug is equivalent to thalidomide. Lenalidomide is used to manage anemia in people with a certain type of myelodysplastic syndrome. Moreover, it is also used for the treatment of multiple myeloma. Multiple myeloma is a bone marrow cancer, in which the normal antibody-producing cells transform into cancerous myeloma cells, producing a wide range of abnormal immunoglobulins or antibodies known as monoclonal proteins. Furthermore, it is also used to treat patients suffering from mantle cell lymphoma. Lenalidomide has proven effectiveness in hematological disorders recognized as myelodysplastic syndromes.
COVID-19 Impact Analysis
- COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the lenalidomide market.
Top Impacting Factors
Increase in prevalence of blood cancer cases across the globe contribute to the growth of the market.
In addition, growth in geriatric population is expected to boost the market growth.
Furthermore, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the lenalidomide market.
On the contrary, rise in awareness about the prevention and treatment of blood cancer and increase in investments in R&D activities to develop novel treatment for blood cancer are expected to offer lucrative growth opportunities for the expansion of the market during the forecast period.
However, high cost associated with drug development along with adverse effects associated with lenalidomide are some of the factors that restrain the market growth.
Market Trends
New Product Launches to Flourish the Market
- In May 2019, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA (venetoclax) in combination with obinutuzumab (GAZYVA) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In May 2019, Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID (lenalidomide) in combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL).
- In April 2021, Food and Drug Administration approved orphan drug designation to CA-4948 for treatment of acute myeloid leukemia and myelodysplastic syndrome.
Key Benefits of the Report
- This study presents the analytical depiction of the lenalidomide market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Lenalidomide Market Report
- Which are the leading market players active in the lenalidomide market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is lenalidomide market?
- What is lenalidomide market prediction in the future?
- Who are the leading global players in the lenalidomide market?
- What are the current trends and predicted trends?
- What are the key benefits of the lenalidomide market report?
Lenalidomide Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By Region |
|
 Key Market Players | Actiza, Dr. Reddy’s. Tsumura, Natco Pharma, LEO Pharma, Toyama Chemical, Celltrion, Dexa Medica, Ablynx, Celegene, HanAll Biopharma. |
Loading Table Of Content...
